Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2676-2685

  Von Minckwitz, Gunter ^a   Raab, Günter ^a   Caputo, Angelika ^a   Schütte, Martin ^a   Hilfrich, Jörn ^a   Blohmer, Jens U ^a   Gerber, Bernd ^a   Costa, Serban D ^a   Merkle, Elisabeth ^a   Eidtmann, Holger ^a   Lampe, Dieter ^a   Jackisch, Christian ^a   Du Bois, Andreas ^a   Kaufmann, Manfred ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HORMONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

ADULT; AGED; ALOPECIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; GERMANY; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; IMAGING SYSTEM; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PALPATION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEUTROPENIA; TAXOIDS; TREATMENT OUTCOME;

EID: 21044454272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.078     Document Type: Article

References (19)

1. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 21:3357-3365, 2003
2. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
3. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
4. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
5. Scholl SM, Pierga J, Asselain B, et al: Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31:1969-1975, 1995
6. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
7. van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19:4224-4237, 2001
8. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1106, 2002
9. von Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999
10. von Minckwitz G, Costa SD, Raab G, et al: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled open phase lib study. J Clin Oncol 19:3506-3515, 2001
11. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
12. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003
13. Sinn HP, Schmid H, Junkermann H, et al: Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54:552-558, 1994
14. Jackisch C, von Minckwitz G, Eidtmann H, et al: Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/ docetaxel in operable breast cancer: Second interim analysis. Clin Breast Cancer 3:276-280, 2002
15. Untch M, Konency G, Ditsch N, et al: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 133)
16. Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 132)
17. Evans TRJ, Yellowlees A, Foster E, et al: Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. Proc Am Soc Clin Oncol 22:8s 2004 (abstr 521)
18. Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: A five year update of the Aberdeen trial. Breast Cancer Res Treat 82:S9, 2003 (suppl 1; abstr 11)
19. Bear HD, Anderson S, Smith RE, et al: A randomized trial comparing preoperative doxorubicin/ cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: Results of NSABP B-27. Presented at 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004